Compare IPWR & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPWR | AYTU |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 23.4M |
| IPO Year | 2013 | N/A |
| Metric | IPWR | AYTU |
|---|---|---|
| Price | $4.32 | $2.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $10.75 | $9.33 |
| AVG Volume (30 Days) | 87.0K | ★ 128.1K |
| Earning Date | 02-26-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $43,136.00 | ★ $63,696,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3,233.33 | $47.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.76 | $0.95 |
| 52 Week High | $7.31 | $3.07 |
| Indicator | IPWR | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 62.15 | 51.17 |
| Support Level | $3.15 | $2.60 |
| Resistance Level | $4.25 | $2.77 |
| Average True Range (ATR) | 0.47 | 0.15 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 67.58 | 12.90 |
Ideal Power Inc is pioneering the development of its broadly patented bidirectional power switches, creating efficient and ecofriendly energy control solutions for electric vehicles, electric vehicle charging, renewable energy, energy storage, UPS / data center, solid-state circuit breaker and other industrial and military applications. The company is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. B-TRAN is a double-sided bidirectional AC switchable to deliver substantial performance improvements over conventional power semiconductors. The primary raw material used in the fabrication of B-TRAN devices is silicon wafers.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.